• In February 2026, Select Medical Holdings Corporation reported mixed fourth-quarter and full-year 2025 results, with revenue rising to US$1,396.63 million for the quarter and US$5,452.83 million for the year, while profitability remained under pressure.
• On the same day, the company declared a US$0.0625 per-share cash dividend and issued 2026 guidance calling for US$5.6 billion to US$5.8 billion in revenue and fully diluted earnings per share of US$1.22 to US$1.32, framing how management sees its earnings power after a year of compressed margins.
• We’ll now examine how this 2026 earnings guidance, following a year of margin pressure, reshapes Select Medical’s existing investment narrative.

Rare earth metals are the new gold rush. Find out which 31 stocks are leading the charge.

Select Medical Holdings Investment Narrative Recap

To own Select Medical today, you need to believe its large post-acute and rehab footprint can convert steady patient demand into healthier margins over time, despite regulatory and cost pressures. The key short term catalyst is whether 2026 earnings land within management’s US$1.22 to US$1.32 EPS guidance after a year of compressed profitability. The biggest near term risk remains reimbursement and cost pressure in critical illness recovery hospitals; the latest update does not remove that concern.

The most relevant new information is the 2026 earnings and revenue guidance, which effectively resets expectations after mixed 2025 results. Management is signaling how it views earnings power at roughly US$5.6 billion to US$5.8 billion of revenue, even as margins remain under pressure. For investors watching expansion in inpatient rehabilitation as a core catalyst, this guidance helps frame how much of that growth may flow through to the bottom line in the near term.

Yet, against this cautious optimism, heavy reliance on government reimbursement still poses a risk investors should be aware of if...

Select Medical Holdings’ valuation narrative projects $6.1 billion in revenue and $233.8 million in earnings by 2028.

Uncover how Select Medical Holdings' forecasts yield a $17.83 fair value, a 20% upside to its current price.

Exploring Other Perspectives

Some of the most pessimistic analysts were already assuming only about US$6.2 billion of revenue and US$210.9 million of earnings by 2028, so after this guidance you should expect their more cautious view on reimbursement risk and debt to potentially shift again as the story develops.

Explore 2 other fair value estimates on Select Medical Holdings - why the stock might be worth as much as 20% more than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Select Medical Holdings research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Select Medical Holdings research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Select Medical Holdings' overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Capitalize on the AI infrastructure supercycle with our selection of the 33 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 23 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• Invest in the nuclear renaissance through our list of 84 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.